Relmada Therapeutics, Inc. Common Stock
RLMDRelmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company leverages its expertise in pain management and neuropharmacology to develop innovative drug candidates aimed at addressing unmet medical needs in chronic pain and related conditions.
Company News
Relmada Therapeutics, a clinical-stage biotechnology company, announced its addition to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026. The company's CEO attributed the achievement to robust 12-month data for its lead candidate NDV-01 in NMIBC treatment and a well-capitalized balance sheet.
Relmada Therapeutics announced presentations of NDV-01 clinical data at the American Urology Association conference in May 2026. Phase 2 data showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer patients. The company's Phase 3 'RESCUE' registrational program remains on track for mid-2026 initiation.
Relmada Therapeutics announced a conference call scheduled for March 19, 2026 at 4:30 PM ET to discuss fourth quarter 2025 financial results and business progress. The clinical-stage biotechnology company is also presenting at the Leerink Partners Global Healthcare Conference and recently completed an oversubscribed $160 million private placement...
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therape...
Relmada Therapeutics strengthens its clinical advisory board by appointing Dr. Yair Lotan as Clinical Advisory Board Chair and Dr. Raj S. Pruthi as CMO-Urology, supporting the development of their NDV-01 program with a planned Phase 3 trial in H1 2026.
